A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322 (NCT01686711) | Clinical Trial Compass
CompletedPhase 4
A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322
Japan207 participantsStarted 2012-09
Plain-language summary
To evaluate the efficacy and safety of coadministration AD-4833 and SYR-322 in patients with diabetes mellitus.
Who can participate
Age range20 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Those judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator.
* Those who can sign and date a written, informed consent form prior to the initiation of any study procedures.
Exclusion Criteria:
* Those with concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease etc.
* Others who are assessed to be ineligible for the study by the investigator or subinvestigator.